Phase I Study of Combination of Sorafenib and LBH589 in Hepatocellular Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs Panobinostat; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 28 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record